EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer

Ya Gao, Ming Liu, Lun Li, Junhua Zhang, Fujian Song, Jinhui Tian iD

Cochrane Database of Systematic Reviews · 21.05.2026 · 2026 (5)

DOI: 10.1002/14651858.cd015072.pub3 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cochrane Database of Systematic Reviews, online erschienen am 21.05.2026. Verfasst von Ya Gao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Dataology, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Immune Checkpoint Inhibitors, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Triple-negative breast cancer (TNBC), an aggressive subtype lacking oestrogen and progesterone receptors and amplification of HER2 receptors, accounts for 12% to 17% of breast cancers. Adjuvant and neoadjuvant chemotherapy improve survival; however, 30% to 40% of early-stage TNBC cases progress to metastatic disease. Recent evidence suggests that combining immune checkpoint inhibitors (PD-1/PD-L1 inhibitors) with chemotherapy may improve pathological complete response and event-free survival. OBJECTIVES: To assess the benefits and harms of immune checkpoint inhibitors (PD-1 or PD-L1 inhibitors) plus chemotherapy compared with chemotherapy for people with early TNBC. SEARCH METHODS: We searched the Cochrane Breast Cancer Group Specialised Register, CENTRAL, MEDLINE, Embase, the WHO ICTRP, and ClinicalTrials.gov up to 6 November 2024. We also searched the reference lists of identified relevant trials or reviews for potentially eligible studies. SELECTION CRITERIA: Randomised controlled trials (RCTs) comparing PD-1 or PD-L1 inhibitors plus chemotherapy with chemotherapy alone in participants with early TNBC. DATA COLLECTION AND ANALYSIS: Pairs of review authors independently identified studies for inclusion and performed data extraction and risk of bias assessment. Outcomes were pathological complete response, event-free survival (EFS), overall survival (OS), health-related quality of life (HRQoL), and overall rates of any adverse events and serious adverse events (SAEs). We calculated hazard ratios (HRs) for time-to-event data, risk ratios (RRs), odds ratios (ORs), or risk differences (RDs) for dichotomous outcomes, and mean differences (MDs) for continuous outcomes with corresponding 95% confidence intervals (CIs). We performed random-effects meta-analyses to summarise the evidence and evaluated the certainty of evidence using the GRADE approach. MAIN RESULTS: We included seven RCTs with a total of 4341 participants. Two trials investigated PD-1 inhibitors (i.e. pembrolizumab), and five investigated PD-L1 inhibitors (i.e. durvalumab, atezolizumab) in the intervention group. Six studies used neoadjuvant chemotherapy (NACT), and one study used adjuvant chemotherapy (ACT) in the control group. The studies cover a five-year follow-up period. Two studies were at low risk of bias for all reported outcomes. The main limitation of the other trials was lack of blinding. PD-1 or PD-L1 inhibitors plus chemotherapy versus chemotherapy alone beforebreast cancer surgery PD-1 or PD-L1 inhibitors plus chemotherapy probably increase pathological complete response rate (RR 1.47, 95% CI 1.15 to 1.86; 6 studies, 1564 participants; moderate-certainty evidence); improve EFS (HR 0.64, 95% CI 0.52 to 0.79; 4 studies, 1789 participants; high-certainty evidence); and probably improve OS (HR 0.56, 95% CI 0.34 to 0.93; 3 studies, 1681 participants; moderate-certainty evidence) compared with chemotherapy alone. There may be little or no difference between PD-1 or PD-L1 inhibitors plus chemotherapy and chemotherapy alone in HRQoL (MD -1.49, 95% CI -3.88 to 0.91; 2 studies, 1395 participants; low-certainty evidence). PD-1 or PD-L1 inhibitors plus chemotherapy probably have little or no effect on any adverse events (OR 0.26, 95% CI 0.05 to 1.24; 3 studies, 1781 participants; moderate-certainty evidence) and treatment-related deaths (RD 0.2%, 95% CI -0.4% to 0.8%; 4 studies, 1761 participants; moderate-certainty evidence) compared with chemotherapy alone. PD-1 or PD-L1 inhibitors plus chemotherapy probably increase immune-related SAEs (OR 1.75, 95% CI 1.15 to 2.67; 5 studies, 2016 participants; moderate-certainty evidence) compared with chemotherapy alone. PD-1 or PD-L1 inhibitors plus chemotherapy versus chemotherapy alone afterbreast cancer surgery There may be little or no difference between PD-1 or PD-L1 inhibitors plus chemotherapy and chemotherapy alone in EFS (HR 1.11, 95% CI 0.87 to 1.42; 1 study, 2199 participants; low-certainty evidence), OS (HR 1.23, 95% CI 0.87 to 1.73; 1 study, 2199 participants; low-certainty evidence), HRQoL (MD -1.02, 95% CI -2.71 to 0.67; 1 study, 2168 participants; low-certainty evidence), any adverse events (OR 3.38, 95% CI 0.93 to 12.33; 1 study, 2177 participants; low-certainty evidence), and treatment-related deaths (RD -0.1%, 95% CI -0.4% to 0.2%; 1 study, 2177 participants; low-certainty evidence). PD-1 or PD-L1 inhibitors plus chemotherapy probably increase immune-related SAEs (OR 1.81, 95% CI 1.47 to 2.24; 1 study, 2177 participants; moderate-certainty evidence) compared to chemotherapy alone. AUTHORS' CONCLUSIONS: Combining PD-1 or PD-L1 inhibitors with chemotherapy compared to chemotherapy alone before breast cancer surgery improves pathological response, EFS, and OS in early TNBC. In contrast, the combination of PD-1/PD-L1 inhibitors with chemotherapy after breast cancer surgery may have little to no effect on EFS and OS in early-stage TNBC when compared with chemotherapy alone. The addition of PD-1 or PD-L1 inhibitors probably increases immune-related SAEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsTriple Negative Breast NeoplasmsFemaleHumansAntibodies, Monoclonal, HumanizedB7-H1 AntigenBiasChemotherapy, AdjuvantDisease-Free SurvivalPathologic Complete ResponseProgrammed Cell Death 1 ReceptorRandomized Controlled Trials as Topic

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsB7-H1 AntigenImmune Checkpoint InhibitorspembrolizumabProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Medical Dataology, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.
  • National Institute of Health and Medical Big Data, Jinan, China.
  • Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou City, China.
  • Lee Kong Chian School of Medicine, Nanyang Technological University, Sigapore, Singapore.
  • Department of Breast Cancer, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

ORCID-Profile: Jinhui Tian

Zitieren

APA

Gao, Y., Liu, M., Li, L., Zhang, J., Song, F., & Tian, J. (2026). Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer. Cochrane Database of Systematic Reviews, 2026(5). https://doi.org/10.1002/14651858.cd015072.pub3

Vancouver

Gao Y, Liu M, Li L, Zhang J, Song F, Tian J. Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer. Cochrane Database of Systematic Reviews. 2026;2026(5). doi:10.1002/14651858.cd015072.pub3

BibTeX
@article{Gao2026,
  author = {Gao, Ya and Liu, Ming and Li, Lun and Zhang, Junhua and Song, Fujian and Tian, Jinhui},
  title = {Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer},
  journal = {Cochrane Database of Systematic Reviews},
  year = {2026},
  volume = {2026},
  number = {5},
  doi = {10.1002/14651858.cd015072.pub3}
}
Kostenlos starten →